Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Downregulation of c-Jun expression and cell cycle regulatory molecules in acute myeloid leukemia cells upon CD44 ligation

Abstract

In the present study, we investigated the mechanism of CD44 ligation with the anti-CD44 monoclonal antibody A3D8 to inhibit the proliferation of human acute myeloid leukemia (AML) cells. The effects of A3D8 on myeloid cells were associated with specific disruption of cell cycle events and induction of G0/G1 arrest. Induction of G0/G1 arrest was accompanied by an increase in the expression of p21, attenuation of pRb phosphorylation and associated with decreased Cdk2 and Cdk4 kinase activities. Since c-Jun is an important regulator of proliferation and cell cycle progression, we analysed its role in A3D8-mediated growth arrest. We observed that A3D8 treatment of AML patient blasts and HL60/U937 cells led to the downregulation of c-Jun expression at mRNA and protein level. Transient transfection studies showed the inhibition of c-jun promoter activity by A3D8, involving both AP-1 sites. Furthermore, A3D8 treatment caused a decrease in JNK protein expression and a decrease in the level of phosphorylated c-Jun. Ectopic overexpression of c-Jun in HL60 cells was able to induce proliferation and prevent the antiproliferative effects of A3D8. In summary, these data identify an important functional role of c-Jun in the induction of cell cycle arrest and proliferation arrest of myeloid leukemia cells because of the ligation of the cell surface adhesion receptor CD44 by anti-CD44 antibody. Moreover, targeting of G1 regulatory proteins and the resulting induction of G1 arrest by A3D8 may provide new insights into antiproliferative and differentiation therapy of AML.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8
Figure 9

Similar content being viewed by others

References

  • Allouche M, Charrad RS, Bettaieb A, Greenland C, Grignon C and Smadja-Joffe F . (2000). Blood, 96, 1187–1190.

  • Aruffo A, Stamenkovic I, Melnick M, Underhill CB and Seed B . (1990). Cell, 61, 1303–1313.

  • Bakiri L, Lallemand D, Bossy-Wetzel E, Yaniv M . (2000). EMBO J., 2, 2056–2068.

  • Bates S, Parry D, Bonetta L, Vousden K, Dickson C and Peters G . (1994). Oncogene, 9, 1633–1640.

  • Behre G, Singh SM, Liu H, Bortolin LT, Christopeit M, Radomska HS, Rangatia J, Hiddemann W, Friedman AD and Tenen DG . (2002). J. Biol. Chem., 277, 26293–26299.

  • Behre G, Smith LT and Tenen DG . (1999). Biotechniques, 26, 24–26.

  • Behre G, Whitmarsh AJ, Coghlan MP, Hoang T, Carpenter CL, Zhang DE, Davis RJ and Tenen DG . (1999). J. Biol. Chem., 274, 4939–4946.

  • Behre G, Zhang P, Zhang DE and Tenen DG . (1999). Methods, 17, 231–237.

  • Binetruy B, Smeal T and Karin M . (1991). Nature, 351, 122–127.

  • Charrad RS, Gadhoum Z, Qi J, Glachant A, Allouche M, Jasmine C, Chomienne C and Smadja-Joffe F . (2002). Blood, 1, 290–299.

  • Charrad RS, Li Y, Delpech B, Balitrand N, Clay D, Jasmin C, Chomienne C and Smadja-Joffe F . (1999). Nat. Med., 5, 669–676.

  • Chou SY, Baichwal V and Ferrell Jr JE . (1992). Mol. Biol. Cell., 3, 1117–1130.

  • Danova M, Giordano M, Mazzini G and Riccardi A . (1990). Leukemia Res., 14, 417–422.

  • Deng T and Karin M . (1994). Nature, 371, 171–175.

  • Elsässer A, Franzen M, Reddy V and Behre G . (2002). ASH [Abstract]. 100, 200.

  • Emig M, Saussele S, Wittor H, Weisser A, Reiter A, Willer A, Berger U, Hehlmann R, Cross NC and Hochhaus A . (1999). Leukemia, 13, 1825–1832.

  • Gitig DM and Koff A . (2000). Methods Mol. Biol., 142, 109–123.

  • Harper JW, Adami GR, Wei N, Keyomarsi K and Elledge SJ . (1993a). Cell, 75, 805–816.

  • Harper JW, Adami GR, Wei N, Keyomarsi K and Elledge SJ . (1993b). Cell, 19, 805–816.

  • Hilberg F, Aguzzi A, Howells N and Wagner . (1993). Nature, 365, 179–181.

  • Hilberg F and Wagner EF . (1992). Oncogene, 7, 2371–2380.

  • Horiguchi-Yamada J, Yamada H, Nakada S, Ochi K and Nemoto T . (1994). Mol. Cell. Biochem., 132, 31–37.

  • Hunter T and Pines J . (1994). Cell, 79, 573–582.

  • Jiang H, Lin J, Su ZZ, Collart FR, Huberman E and Fisher PB . (1994). Oncogene, 9, 3397–3406.

  • Kallunki T, Su B and Tsigelny I . (1994). Genes Dev., 8, 2996–3007.

  • Kantarjian H . (1999). Semin. Hematol., 36, 16–25.

  • Kiaris H, Schally AV, Sun B, Armatis P and Groot K . (1999). Oncogene, 18, 7168–7173.

  • Kirschmeier PT, Housey GM, Johnson MD, Perkins AS and Weinstein IB . (1988). DNA, 7, 219–225.

  • Kovary K and Bravo R . (1991). Mol. Cell. Biol., 11, 4466–4472.

  • Kuhn LC . (1994). Bailliere's Clin. Haematol., 7, 763–785.

  • Liesveld JL, Dipersio JF and Abboud CN . (1994). Leukemia Lymphoma, 14, 19–28.

  • Liebermann DA, Hoffman B and Steinman RA . (1995). Oncogene, 11, 199–210.

  • Lowell C-A and Berton G . (1999). J. Leukoc. Biol., 65, 313–320.

  • Lowenberg B, Downing JR and Burnett A . (1999). N. Engl. J. Med., 341, 1051–1062.

  • Matsushime H, Quelle DE, Shurtleff SA, Shibuya M, Sherr CJ and Kato JY . (1994). Mol. Cell. Biol., 14, 2066–2076.

  • Meyerson M and Harlow E . (1994). Mol. Cell. Biol., 14, 2077–2086.

  • Milde-Langosch K, Bamberger AM, Methner C, Rieck G and Loning T . (2000). Int. J. Cancer, 87, 468–472.

  • Minden A, Lin A, Smeal T, Derijard B, Cobb M, Davis R and Karin M . (1994). Mol. Cell. Biol., 14, 6683–6688.

  • Miyake K, Underhill CB, Lesley J and Kincade PW . (1990). J. Exp. Med., 172, 69–75.

  • Moll J, Khaldoyanidi S, Sleeman JP, Achtnich M, Preuss I, Ponta H and Herrlich P . (1998). J. Clin. Invest., 102, 1024–1034.

  • Muller R, Mumberg D and Lucibello FC . (1993). Biochim. Biophys. Acta, 1155, 151–179.

  • Nead MA, Baglia LA, Antinore MJ, Ludlow JW and McCance DJ . (1998). EMBO J., 17, 2342–2352.

  • Nishitani J, Nishinaka T, Cheng CH, Rong W, Yokoyama KK and Chiu R . (1999). J. Biol. Chem., 274, 5454–5461.

  • Patel R, Bartosch B and Blank JL . (1998). J. Cell Sci., 111, 2247–2255.

  • Pisani F, Del Poeta G, Aronica G, Venditti A, Caravita T and Amadori S . (1997). Ann. Hematol., 75, 145–147.

  • Rangatia JS, Vangala RK, Treiber N, Zhang P, Radomska HS, Tenen DG, Hiddemann W and Behre G . (2002). Mol. Cell. Biol., 22, 8681–8785.

  • Reuss-Borst MA, Buhring HJ, Klein G and Muller CA . (1992). Ann. Hematol., 65, 169–174.

  • Reddy V, Iwama A, Iotzova G, Schulz M, Elsasser A, Vangala RK, Tenen DG, Hiddemann W and Behre G . (2002). Blood, 100, 483–490.

  • Sanford J, Shattil, Hirokazu, Kashiwagi and Pampori N . (1998). Blood, 91, 2645–2657.

  • Savatier P, Huang S, Szekely L, Wiman KG and Samarut J . (1994). Oncogene, 9, 809–818.

  • Schreiber M, Kolbus A, Piu F, Szabowski A, Mohle-Steinlein U, Tian J, Karin M, Angel P and Wagner EF . (1999). Genes Dev., 13, 607–619.

  • Shaulian E and Karin M . (2001). Oncogene, 20, 2390–2400.

  • Sherr CJ . (1994). Stem Cells, 1, 47–55.

  • Shim J, Lee H, Park J, Kim H and Choi EJ . (1996). Nature, 381, 804–806.

  • Sievers EL . (2000). Curr. Opin. Oncol., 12, 30–35.

  • Slack RS, Hamel PA, Bladon TS, Gill RM and McBurney MW . (1993). Oncogene, 8, 1585–1591.

  • Smeal T, Binetruy B, Mercola DA, Birrer M and Karin M . (1991). Nature, 354, 494–496.

  • Smith MJ and Prochownik EV . (1992). Blood, 79, 2107–2115.

  • Steinman RA, Hoffman B, Iro A, Guillouf C, Liebermann DA and El-Houseini ME . (1994). Oncogene, 9, 3389–3396.

  • Steinman RA, Jianping H, Beatrice Y, Julie PG, Ball ED and Nguyen A . (1998). Blood, 91, 4531–4542.

  • Tenen DG, Hromas R, Licht JD and Zhang DE . (1997). Blood, 90, 489–519.

  • Theil EC . (1990). J. Biol. Chem., 265, 4771–4774.

  • Trayner ID, Bustorff T, Etches AE, Mufti GJ, Foss Y and Farzaneh F . (1998). Leukemia Res., 22, 537–547.

  • Vangala RK, Heiss-Neumann MS, Rangatia JS, Singh SM, Schoch C, Tenen DG, Hiddemann W and Behre G . (2002). Blood, 101, 270–277.

  • Verfaillie CM . (1998). Blood, 92, 2609–2612.

  • Waxman S . (2000). Leukemia, 14, 491–496.

  • Wei P, Inamdar N and Vedeckis WV . (1998). Mol. Endocrinol., 12, 1322–1333.

  • Wisdom R, Johnson RS and Moore C . (1999). EMBO J., 18, 188–197.

Download references

Acknowledgements

We thank Dr Dirk Eick and Alloy Sheppers for valuable comments and useful discussions, Christian Kurzreder, Doreen Westhaus and Vijay Rawat for help with flow cytometry experiments and Susanne Schnittger for providing AML patient samples. This work was supported by a DFG (German research foundation) grant given to GB (2042/2-1).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Gerhard Behre.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Peer Zada, A., Singh, S., Reddy, V. et al. Downregulation of c-Jun expression and cell cycle regulatory molecules in acute myeloid leukemia cells upon CD44 ligation. Oncogene 22, 2296–2308 (2003). https://doi.org/10.1038/sj.onc.1206393

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1206393

Keywords

This article is cited by

Search

Quick links